Gastroenterology – Page 2

Zanidatamab-Based Triplet Therapy Redefines Survival Expectations in HER2-Positive Gastric Cancer: Insights from a Phase 1b/2 Study

By MedXY 01/12/2026

A phase 1b/2 trial reveals that combining the bispecific antibody zanidatamab with tislelizumab and chemotherapy yields a 75.8% response rate and an impressive median overall survival of 32.4 months in first-line HER2-positive gastric and gastroesophageal junction cancer.

Gastroenterology news Oncology

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients

By MedXY 01/12/2026

A prospective study demonstrates that concurrent antiviral prophylaxis effectively mitigates HBV reactivation risk in HCC patients treated with PD-1/L1 inhibitors, regardless of baseline viral load, challenging traditional clinical trial exclusion criteria.

Gastroenterology news Oncology

Erdafitinib Yields 55% Response Rate in FGFR-Altered Advanced Cholangiocarcinoma: Insights from a Pooled Phase 2 Analysis

By MedXY 01/11/2026

A pooled analysis of the RAGNAR and LUC2001 trials demonstrates that erdafitinib provides a robust objective response rate of 55% and a median overall survival of 18.1 months in pretreated patients with FGFR-altered advanced cholangiocarcinoma.

Gastroenterology news Oncology

MAPK Pathway Mutations Drive Resistance to Ivosidenib in IDH1-Mutant Cholangiocarcinoma by Blunting Interferon Signaling

By MedXY 01/11/2026

A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing critical interferon-gamma-mediated antitumor responses.

Gastroenterology news Oncology

Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer

By MedXY 01/11/2026

A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.

Gastroenterology news Public Health

Adherence to the Planetary Health Diet Index Significantly Lowers MASLD Risk: A Global and Individual-Level Analysis

By MedXY 01/11/2026

A comprehensive study integrating global and individual data reveals that adherence to the Planetary Health Diet Index (PHDI) provides significant protection against metabolic dysfunction-associated steatotic liver disease (MASLD), highlighting a sustainable approach to managing the global liver disease epidemic.

Gastroenterology news Public Health

The Double-Win Diet: How the Planetary Health Index Protects Your Liver and the Earth

By MedXY 01/11/2026

This article explores the groundbreaking link between the Planetary Health Diet Index (PHDI) and reduced risks of metabolic dysfunction-associated steatotic liver disease (MASLD), offering evidence-based insights for personal health and environmental sustainability.

Diabetes & Endocrinology Gastroenterology news

Healthy Nordic Diet vs. Anti-Lipogenic High-Fat Diet: Superior Cardiometabolic Outcomes in the NAFLDiet Trial

By MedXY 01/11/2026

The NAFLDiet trial reveals that while both anti-lipogenic LCPUFA and Healthy Nordic Diets reduce liver fat, the Nordic diet offers superior benefits for weight loss, glycemic control, and systemic inflammation in patients with type 2 diabetes or prediabetes.

Clinical Updates Gastroenterology news

Optimizing MASH Management: Synergistic Effects of Resmetirom, GLP-1 Receptor Agonists, and Weight Loss in the MAESTRO-NASH Secondary Analysis

By MedXY 01/10/2026

This review synthesizes findings from the MAESTRO-NASH trial, highlighting that Resmetirom's efficacy is maintained alongside GLP-1 RAs and SGLT2 inhibitors, while being significantly enhanced by concurrent weight loss.

Diabetes & Endocrinology Gastroenterology news

Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial

By MedXY 01/10/2026

The SYNERGY-NASH trial demonstrates that Tirzepatide significantly improves MASH resolution and liver fibrosis. This effect is driven by substantial weight loss, improved glycemic control, and liver fat normalization, highlighting a transformative approach for patients with metabolic-related liver disease.

Gastroenterology news Oncology

AXL: The Double-Edged Sword in Colorectal Cancer Treatment

By MedXY 01/09/2026

Researchers have identified AXL expression as a critical biomarker in colorectal cancer. While it usually signals treatment resistance, a new study reveals that AXL-high tumors with KRAS mutations respond significantly better to immunotherapy, paving the way for more personalized oncology.

Gastroenterology news Oncology

Precision Rechallenge: Liquid Biopsy CGP Refines Patient Selection in Metastatic Colorectal Cancer

By MedXY 01/08/2026

The randomized CAVE-2 GOIM trial demonstrates that while adding avelumab to cetuximab rechallenge does not improve survival in metastatic colorectal cancer, liquid biopsy-based genomic hyper-selection identifies a subgroup of patients with significantly improved outcomes, establishing a new standard for precision oncology.

Gastroenterology news Oncology

HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation

By MedXY 01/08/2026

A Phase Ib/II trial evaluating the combination of XL888 (an HSP90 inhibitor) and pembrolizumab in metastatic pancreatic adenocarcinoma found that while the regimen was safe and induced systemic immune modulation, it failed to alter the tumor microenvironment or improve clinical outcomes.

Gastroenterology news Oncology

Dual-Action ICyM2 Nano-Platform Dismantles Pancreatic Cancer Stromal Barriers and Ignites STING-Mediated Immunity

By MedXY 01/08/2026

Researchers have developed ICyM2, a carrier-free nanoaggregate that combines mitochondrial phototherapy with STING activation. This platform effectively remodels the dense pancreatic cancer stroma, triggers immunogenic cell death, and synergizes with PD-1 inhibitors to convert immunologically 'cold' tumors into 'hot' responsive environments.

Gastroenterology news Oncology

Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer

By MedXY 01/08/2026

A phase 1/2 trial demonstrates the safety and clinical potential of nonengineered, multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma, highlighting durable T cell persistence and antigen spreading as key correlates of clinical benefit.

Gastroenterology Infectious Diseases news

Functional Cure Within Reach: GSK’s Bepirovirsen Meets Primary Endpoints in Pivotal Phase III Chronic Hepatitis B Trials

By MedXY 01/07/2026

GSK has announced positive Phase III results for Bepirovirsen, an antisense oligonucleotide that achieves functional cure in chronic hepatitis B patients. By targeting viral RNA and HBsAg, the drug offers a finite treatment path, potentially transforming global hepatology standards and replacing lifelong therapy.

Diabetes & Endocrinology Gastroenterology news

SGLT2 Inhibitors Emerge as Superior Choice for Cardiovascular Protection in Patients with T2DM and MASLD

By MedXY 01/07/2026

A nationwide target trial emulation reveals that SGLT2 inhibitors significantly reduce major adverse cardiovascular events and mortality compared to other oral antidiabetics in patients with concurrent T2DM and MASLD, with benefits partially mediated by liver disease regression.

Gastroenterology news Oncology

Neoadjuvant Chemoradiotherapy vs. Surgery with Adjuvant Therapy for ESCC: Five-Year Outcomes Challenge the Universal Standard

By MedXY 01/06/2026

A Phase 3 randomized clinical trial finds no significant difference in 5-year overall survival between neoadjuvant chemoradiotherapy and surgery with adjuvant therapy for locally advanced ESCC, emphasizing the need for personalized treatment strategies based on pathological response.

Gastroenterology news Oncology

Triple-Drug Regimen with Tiragolumab and Atezolizumab Shows Superior Response in First-Line Esophageal Cancer: The MORPHEUS-EC Trial

By MedXY 01/06/2026

The phase 1b/2 MORPHEUS-EC trial demonstrates that adding the anti-TIGIT antibody tiragolumab to atezolizumab and chemotherapy significantly improves objective response rates (67.7%) in patients with previously untreated, locally advanced or metastatic esophageal cancer, providing a promising new therapeutic strategy.

Gastroenterology news Oncology

Dual Checkpoint Inhibition: Tiragolumab and Atezolizumab Set New Survival Benchmarks in Advanced Esophageal Squamous Cell Carcinoma

By MedXY 01/06/2026

The Phase 3 SKYSCRAPER-08 trial demonstrates that adding the anti-TIGIT tiragolumab and anti-PD-L1 atezolizumab to chemotherapy significantly extends overall survival and progression-free survival in patients with treatment-naive, unresectable esophageal squamous cell carcinoma.